Upside Visualized on BioCryst Pharma (BCRX); Sudden Bullish Activity for XTL Biopharma (XTLB)


Shares of BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) surged to touch the $6.75 mark in early trade Thursday after analysts at Ladenburg Thalmann initiated coverage on the company’s stock with a Buy ratig and a price target of $11.00

The biotechnology company expects to release its fourth-quarter and full-year 2016 earnings report on Monday, February 27 before the market open.

BCRX stock is trading at $6.45, up $0.30 (or +4.79%) and 1.29M of its shares changed hands so far

BioCryst Pharmaceuticals, which designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases, have 73.76M shares outstanding and BCRX stock 52-week range is from $1.74 to $7.56 per share.



XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) shares rose for a second straight session Thursday on no relevant news from the company that may explain the stock’s rally.

The biopharmaceutical company recently added two internationally-recognized experts to its clinical advisory board to support a Phase II trial evaluating its investigational drug hCDR1 in Sjögren’s syndrome -a chronic disorder of the immune system -.

XTLB stock is changing hands at $3.80, up $0.73 (or +23.61%) with 1.54M shares traded so far, representing a large increase in activity versus its average volume of 13,346 shares

XTL Biopharmaceuticals, which engages in the acquisition and development of pharmaceutical products for the treatment of unmet medical needs, has 273.53M shares outstanding and XTLB stock one-year range is between $2.55 and $7.85 per share.


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at